FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data.
The post Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs appeared first on MedCity News.
